NEUROCRINE BIOSCIENCES INC Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
NEUROCRINE BIOSCIENCES INC (NBIX) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $300.00 thousand as of 2021-06-30, per its 10-Q filed 2021-08-03.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2021-08-03
- 2021-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $300.00K.
- 2020-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $3.20M.
- 2019-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $82.00K.
- 2019-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $119.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss as first filed |
|---|---|---|
| 2021-06-30 | $300.00K 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $3.20M 10-Q · filed 2020-05-06 | |
| 2019-09-30 | $82.00K 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $119.00K 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $506.00K 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $127.00K 10-K · filed 2020-02-07 | $2.17M 10-K · filed 2019-02-08 |
| 2017-12-31 | $2.17M 10-K · filed 2020-02-07 | $1.85M 10-K · filed 2019-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |